Lighthouse receives $49.2 million NIA grant to advance phase 2 study of Alzheimer’s disease

LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis

Healthium and C-CAMP launch innovations program for surgical and medical technologies

Nanavati Max Hospital performs 4-hour simultaneous pancreas-kidney transplant on 25-year-old with Type-1 diabetes

The complex four-hour surgery was performed by a multidisciplinary team of doctors

SIMS Hospital successfully treats rare skin tumour with skull and scalp reconstruction

The patient had been battling DFSP for over eight years, enduring multiple recurrences despite three previous surgeries

BioAge Labs doses first patient in BGE-102 phase 1 trial

The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants

Zydus receives NOC from Health Canada for ZDS-Varenicline Tablets 0.5 &1 mg

This is the group’s first NoC approval in Canada

Roche presents new Alzheimer’s research at AAIC 2025

Roche also shared the design of its upcoming Phase III TRONTIER 1 and 2 trials investigating trontinemab in people with early symptomatic Alzheimer’s disease

Duke Street Bio receives FDA fast track designation for PARP1-selective inhibitor with CNS activity

Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need

EMA starts review of sodium oxybate in alcohol dependence

Review will evaluate effectiveness in treating alcohol withdrawal syndrome and supporting abstinence, as well as measures to mitigate risk of abuse

Teijin Pharma receives approval for additional indication for XEOMIN in Japan